Treatment of systemic sclerosis with severe interstitial lung disease (ILD) unresponsive to cyclophosphamide (CYC) with mycophenolate mofetil (MMIT).

被引：0
|
作者：
Mouthon, L
Valeyre, D
Brauner, M
Lamberto, C
André, MH
Mahr, A
Guillevin, L
机构：
[1] Hop Avicenne, Dept Internal Med, F-93009 Bobigny, France
[2] Hop Avicenne, Dept Pneumol, F-93009 Bobigny, France
[3] Hop Avicenne, Dept Radiol, F-93009 Bobigny, France
[4] Hop Avicenne, Funct Explorat Dept, F-93009 Bobigny, France
来源：
ARTHRITIS AND RHEUMATISM | 2003年 / 48卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1435
引用
收藏
页码：S559 / S559
页数：1
相关论文
共 50 条
  • [1] MYCOPHENOLATE MOPHETIL IN THE TREATMENT OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE (SSC-ILD) IN PATIENTS UNRESPONSIVE TO CYCLOPHOSPHAMIDE (CYC)
    Cuomo, G.
    Abignano, G.
    Iudici, M.
    Petrillo, A.
    Valentini, G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : S167 - S167
  • [2] Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis
    Schneider, Udo
    Siegert, Elise
    Glaser, Sven
    Kruger, Klaus
    Krause, Andreas
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2021, 80 (09): : 868 - 878
  • [3] Advancements in the treatment of interstitial lung disease in systemic sclerosis with the approval of mycophenolate mofetil
    Takada, Toshinori
    Aoki, Ami
    Shima, Kenjiro
    Kikuchi, Toshiaki
    RESPIRATORY INVESTIGATION, 2024, 62 (06) : 1242 - 1246
  • [4] Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease
    Gkiouras, Konstantinos
    Grammatikopoulou, Maria G.
    Simopoulou, Theodora
    Daniil, Zoe
    Bogdanos, Dimitrios P.
    CLINICAL RHEUMATOLOGY, 2021, 40 (08) : 3379 - 3380
  • [5] Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease
    Konstantinos Gkiouras
    Maria G. Grammatikopoulou
    Theodora Simopoulou
    Zoe Daniil
    Dimitrios P. Bogdanos
    Clinical Rheumatology, 2021, 40 : 3379 - 3380
  • [6] Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
    Athanasios Koutroumpas
    Athanasios Ziogas
    Ioannis Alexiou
    Georgia Barouta
    Lazaros I. Sakkas
    Clinical Rheumatology, 2010, 29 : 1167 - 1168
  • [7] Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
    Koutroumpas, Athanasios
    Ziogas, Athanasios
    Alexiou, Ioannis
    Barouta, Georgia
    Sakkas, Lazaros I.
    CLINICAL RHEUMATOLOGY, 2010, 29 (10) : 1167 - 1168
  • [8] COMPARISON OF LONG-TERM CYCLOPHOSPHAMIDE (CY) AND MYCOPHENOLATE MOFETIL (MMF) EFFICACY AND SAFETY IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND INTERSTITIAL LUNG DISEASE (ILD)
    Koneva, O.
    Ovsyannikova, O.
    Desiniva, O.
    Garzanova, L.
    Ananieva, L.
    Starovoytova, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1108 - 1109
  • [9] LONG-TERM OUTCOME OF A TARGETED TREATMENT REGIMEN WITH IV CYCLOPHOSPHAMIDE (CYC) IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND INTERSTITIAL LUNG DISEASE (ILD)
    Ottewell, Lesley
    Walker, Karen
    Griffiths, Bridget
    RHEUMATOLOGY, 2009, 48 : I76 - I76
  • [10] Azathioprine Compared to Mycophenolate Mofetil Treatment in Patients with Interstitial Lung Disease Associated with Systemic Sclerosis
    Shell, J.
    Kapralik, J.
    Jones, A.
    Farooqi, M.
    Beattie, K.
    Kolb, M. R.
    Cox, G. P.
    Scallan, C. J.
    Larche, M. J.
    Khalidi, N. A.
    Hambly, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
12345